
 Mankind Pharma Limited IPO - Price, Lot size, Open date, GMP & Review - Online Demat, Trading, and Mutual Fund Investment in India - Fisdom                Skip to content          Products    Stocks      IPOs & more      Mutual Funds       Pension Funds  Private Wealth Resources    Research      One Percent Academy      Blogs      Calculators   Company    About us      Careers      Contact us   LoginDownload app   Blog    Stock MarketsStock Markets                             Mankind Pharma Limited IPO – Price, Lot size, Open date, GMP & Review RudriRawellWritten by - Rudri RawellApril 22, 2023  6 minutes  The stock market in India has been experiencing a turbulent start to 2023, with only a few companies coming up with their IPOs. However, for investors who are looking for new investment opportunities, Mankind Pharma Ltd IPO seems like a glimmer of hope. As one of the leading pharmaceutical companies in India, Mankind Pharma has been delivering quality products and services for over 25 years. With a strong focus on research and development, the company has been expanding its product portfolio and footprint globally. This blog will provide an in-depth analysis of Mankind Pharma Ltd IPO and its potential for investors looking to invest in the pharmaceutical sector.Mankind Pharma Limited IPO will open for subscription on 25th April 2023 and will close on 27th April 2023.Here are all the essential details of Mankind Pharma Limited IPO, including investment price band, allotment date, GMP, benefits, risks of investing in this IPO, and more.  Table of Contents  hide   1 IPO Details   2 Mankind Pharma Limited IPO Objectives   3 Top things to know about Mankind Pharma Limited IPO   4 Financials of the company   5 Strengths of the company   6 Risks of investment   7 What is the Grey Market Premium (GMP) of Mankind Pharma Limited IPO?   8 Should you apply for Mankind Pharma Limited IPO?   9 How to apply for Mankind Pharma Limited IPO?   10 Mankind Pharma Limited IPO FAQs   11 Also read.. IPO Details The key details of the Mankind Pharma Limited IPO are as under. IPO Size The size of the IPO and different categories of the issue are:CategoryDetailsIPO Opening Date25th April 2023 IPO Closing Date27th April 2023ListingNSE, BSEIssue TypeBook Built Issue IPOFace Value of sharesRe. 1 per shareIPO Price BandRs. 1026 – Rs. 1080 per shareIPO SizeRs. 4,326 crores (40,058,844 shares)Offer For SaleRs. 4,326 crores (40,058,844 shares)Fresh IssueNilIPO Dates The important dates for the Mankind Pharma Limited IPO are highlighted below:EventDateOpening date25th April 2023Closing Date27th April 2023Allotment date3rd May 2023Refund Date4th May 2023Share Credit Date5th May 2023Listing Date8th May 2023IPO Lot Sizes Investors can subscribe to the shares of Mankind Pharma Limited IPO  in pre-defined lots. The details of the lot sizes for this IPO are mentioned below: CategoryDetailsInvestments in lots (for retail investors)Minimum – 1 lotMaximum – 14 lotsInvestment amount (for retail investors)Minimum – Rs. 14,040Maximum – Rs. 1,96,560Shares (HNI)Minimum – 15Maximum – 71IPO ReservationThe categories of eligible investors and their share in the IPO are tabled below:Category of InvestorReservation PercentageQIB (Qualified Institutional Buyers)50%NII (Non-Institutional Bidders)15%RII (Retail Individual Investors)35%Mankind Pharma Limited IPO ObjectivesThis IPO is an entirely Offer for Sale issue, which means that existing promoters of Mankind Pharma Ltd plan to offload some of their stake in the company. The company will not receive any proceeds from the offer and all the offer proceeds will be received by the selling shareholders.Top things to know about Mankind Pharma Limited IPOEstablished in 1991, Mankind Pharma Limited is a leading pharmaceutical company that specializes in developing, manufacturing, and distributing pharmaceutical formulations across a range of acute and chronic therapeutic areas, as well as consumer healthcare products.The company has a significant presence in the Indian market, catering to various therapeutic fields, such as anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. It boasts an impressive portfolio of over 36 brands, which includes popular names like Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, and Glimestar-M.Mankind Pharma has a vast distribution network of medical representatives in the Indian pharmaceutical market, which is one of the largest in the industry. More than 80% of doctors in India prescribe their formulations, making it one of the most trusted and reliable names in the field. In fact, the company was ranked 4th in terms of domestic sales during the Financial Year 2022, a testament to its success and growth.Financials of the companyMankind Pharma Limited financials are given in the table below:Year Total Assets (Rs. In crores)Operating Revenue (Rs. In crores)Profit after tax (Rs. In crores)Basic EPS(Rs.)Diluted EPS(Rs.)RONW(%)Mar-20229,1487,7811,45335.7835.7823.29Mar-20216,3736,2141,29331.5931.5926.80Mar-20205,0735,8651,05625.7225.7229.56(Source: RHP)Strengths of the companySome of the key strengths of Mankind Pharma Limited that investors can take note of are:CategoryDetailsBusiness model Mankind Pharma Limited has established itself as a leading domestic pharmaceutical company, with significant potential for further growth.The company has a strong presence in the consumer healthcare sector, which is continuously growing and has high brand recall among customers.The company has successfully leveraged its corporate brand to build and scale its brands, resulting in a diverse portfolio with strong rankings across key therapeutic areas.Mankind Pharma has a wide market and distribution coverage, with a focus on providing affordable and accessible healthcare solutions.Faster growthMankind Pharma has been able to outpace the Indian Pharmaceutical Market (IPM) with its volume-led growth strategy.Risks of investmentHere are some of the risks that investors of Mankind Pharma Limited IPO should know:CategoryDetailsBusiness viability and profitabilityThe company may face challenges in obtaining and maintaining intellectual property rights for its brands, which could lead to increased competition and decreased profitability. Additionally, protecting proprietary information may be difficult.Dependence on subsidiaries exposes the company to significant risks. Any financial or operational issues within these subsidiaries could adversely affect the company’s overall performance.Political, economic, or other factors beyond the company’s control may have an adverse effect on its business and results of operations. Uncertainties surrounding regulatory changes, government policies, and global events could lead to increased volatility and risk.Delays or defaults in customer payments and receivables could adversely impact profits and affect cash flows. This risk is particularly relevant in a highly competitive market with multiple players vying for business.CompetitionDue to the fragmented nature of the industry segments in which the company operates, it faces competition from other large and small players. Business interruption risks may arise from internal and external factors, which could impact operations.What is the Grey Market Premium (GMP) of Mankind Pharma Limited IPO?As of April 20th, 2023, the grey market premium for the shares of Mankind Pharma Limited is approximately between Rs. 74-82 as per market observers.Should you apply for Mankind Pharma Limited IPO?Mankind Pharma has over 36 brands in its portfolio and one of the largest distribution networks of medical representatives in the Indian pharmaceutical market, with over 80% of doctors prescribing their formulations. This IPO presents an opportunity for investors looking to gain exposure to the Indian healthcare industry.How to apply for Mankind Pharma Limited IPO?Investors can invest in this IPO through the Fisdom app.Mankind Pharma Limited IPO FAQs1. Which are the popular brand offerings of Mankind Pharma Ltd?Mankind Pharma Ltd owns some of the popular brands like ‘Manforce’ condoms, pregnancy test kit Prega News, emergency contraceptive brand Unwanted-72 and antacid powders (Gas-O-Fast) among others.2. Which companies are the competitors of Mankind Pharma Ltd?Some of Mankind Pharma’s competitors include Cipla Ltd, Sun Pharma, Zydus Lifesciences, Alkem Laboratories, and JB Chemicals & Pharmaceuticals.3. What is the GMP of Mankind Pharma Limited?The GMP of Mankind Pharma Limited as on 20th April 2023 ranged between approximately Rs. 74-82 per share.4. Do I need a Demat account to apply for Mankind Pharma Ltd IPO?Yes, to apply for any IPO, you need to have a Demat account. To open a Demat account today, you can download the Fisdom app on your smartphone.Also read..Favorite Sectors of Mutual Funds in Oct 2022Sectoral Mutual Funds | 5 Best Sector Funds for 2022  Stock Markets  Large Cap Stocks – What is it, Features & Factors to be Considered 08 Jun  9 minutes   Stock Markets  Beta in Indian stocks – Types, Should you invest in high beta stocks? 07 Jun  8 minutes   Stock Markets  Top SIX Online Stock Market Courses in India-2023 05 Jun  8 minutes   FeaturedStock Markets  IKIO Lighting Limited IPO – Price, Lot size, Open date, GMP & Review 05 Jun  6 minutes   Stock Markets  Types of Earnings Per Share(EPS) – Calculation & How to Use Them  01 Jun  10 minutes   FeaturedStock Markets  Top Traders in India 31 May  9 minutes   Stock Markets  What are monopoly stocks? Top monopoly stocks in India 30 May  11 minutes   Stock Markets  Hedging – What is it, Types, Strategies, FAQs 29 May  8 minutes   Stock Markets  Put Call Ratio (PCR) – Definition, Formula and Calculation 29 May  7 minutes   Stock Markets  Can stocks make you rich? What are investment options in stock markets?  28 May  7 minutes   Stock Markets  Central Pivot Range – What is it? Calculation, Interpretation & Benefits 28 May  7 minutes   Stock Markets  BSE Sensex: What is it? List of stocks on Sensex, History, Calculation 25 May  6 minutes
                      